Physician profile
Cameron D Snell
NPI 1730513052
$3,169.66
in general payments reported to CMS, 2019-2025
31 companies · $931 in 2025
The $931 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $219 · 2023: $1,053 · 2024: $581 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891 · Travel and Lodging: $596 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.79 |
| Travel and Lodging | $595.72 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $736.47 | 2023 | Da Vinci Surgical System |
| Janssen Biotech, INC. | $356.82 | 2021-2025 | Erleada, Balversa, Akeega |
| Dendreon Pharmaceuticals LLC | $351.86 | 2021-2025 | Provenge |
| Endo Pharmaceuticals INC. | $179.43 | 2021-2024 | Xiaflex |
| Astellas Pharma US INC | $159.56 | 2021-2022 | |
| Endo USA, INC. | $132.43 | 2025 | Xiaflex |
| Merck Sharp & Dohme LLC | $130.91 | 2021-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Sumitomo Pharma America, INC. | $128.85 | 2023-2025 | Orgovyx, Gemtesa |
| Vertex Pharmaceuticals Incorporated | $101.28 | 2024-2025 | |
| Axonics, INC. | $98.96 | 2022-2024 | Bulkamid, Axonics |
| Urogen Pharma, INC. | $97.22 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $85.21 | 2023-2025 | Adstiladrin |
| Amgen INC. | $80.90 | 2021-2022 | |
| Teleflex LLC | $78.27 | 2023-2024 | Urolift |
| Calyxo, INC. | $44.21 | 2024-2025 | Cvac Aspiration System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $39.33 | 2021 | |
| Progenics Pharmaceuticals, INC. | $35.72 | 2023-2024 | Pylarify |
| Csl Behring | $34.98 | 2025 | Andembry |
| Myriad Genetic Laboratories, INC. | $34.79 | 2023-2024 | Prolaris |
| Antares Pharma, INC. | $32.23 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $32.03 | 2025 | |
| Telix Pharmaceuticals | $30.01 | 2024-2025 | Illuccix |
| Blue Earth Diagnostics | $28.84 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $23.78 | 2022 | |
| Procept Biorobotics Corporation | $19.86 | 2025 | |
| Pfizer INC. | $17.56 | 2025 | |
| Myovant Sciences INC. | $16.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.85 | 2025 | Airsupra |
| Verity Pharmaceuticals INC. | $16.31 | 2023 | Trelstar |
| Novo Nordisk INC | $14.28 | 2024 | Rivfloza |
| Coloplast Corp | $13.82 | 2023 | Speedicath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Snell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.